Introduction {#Sec1}
============

Behçet's disease (BD) is a multi-system inflammatory disease characterized by recurrent oral and genital ulcers, uveitis, and skin lesions. Although the etiology and pathogenesis of BD are still uncertain, multiple genetic factors have been linked to BD^[@CR1],[@CR2]^. Among them, *HLA-B\*51* appears to be the most strongly associated known genetic risk to BD in different ethnic groups^[@CR2]^.

*MICA* (major histocompatibility complex class I chain related gene A), located only 46 kb centromeric of *HLA-B*, is a highly polymorphic gene. It normally expresses on the cell membrane, and functions in immune activation under cellular stress conditions, such as infections, tissue injury, pro-inflammatory signals, and malignant transformation^[@CR2]^. The *MICA* transmembrane (TM) A6 allele and the *MICA*\*009 allele were associated with BD in multiple previous reports^[@CR3]--[@CR11]^. According to updated IMGT/HLA database, there are 107 *MICA* alleles identified. The *MICA*\*009 can be further subtyped into *MICA*\*00901, *MICA*\*0090201 and *MICA*\*0090202. The only difference between the *MICA*\*00901 and the *MICA*\*049 is at codon 335 in exon 6 (<https://www.ebi.ac.uk/ipd/imgt/hla/align.html>). In the previous studies^[@CR5],[@CR8]--[@CR11]^, the ambiguity between the *MICA*\*009 allele and the *MICA*\*049 allele was not addressed, because exon 6 was not studied. Therefore, the *MICA*\*009 allele maybe mixed with the *MICA*\*049 allele. Here, we examined the association between *MICA* and BD in a Han Chinese cohort with *MICA* sequencing approach, along with a simple tetra-primer amplification refractory mutation system-polymerase chain reaction (T-ARMS-PCR) method to discriminate between the *MICA*\*00901 allele and the *MICA*\*049 allele.

Results {#Sec2}
=======

The frequencies of *MICA* alleles in the 41 BD patients and 197 healthy controls were shown in Table [1](#Tab1){ref-type="table"}. There were 8 different *MICA* alleles in patients and 16 in controls. The frequency of *MICA*\*049 was significantly higher in the patient group (24.4% in BD versus 4.3% in control, OR = 38.16, *P* = 6.52 × 10^−10^). However, the frequency of *MICA*\*009 (including *MICA*\*009:01 and *MICA*\*009:02) was similar between the two groups (8.5% versus 6.6%, OR = 1.32, *P* = 0.53).Table 1Comparison of *MICA* alleles between BD patients and controls.*MICA* AllelePatients n = 82 (%)Controls n = 394 (%)χ^2^*P* valueOR (95% CI)002:018 (9.8)65 (16.5)0040 (0.0)3 (0.8)007:010 (0.0)7 (1.8)008 (:01 or :04)13 (15.9)91 (23.1)008:020 (0.0)4 (1.0)009:017 (8.5)24 (6.1)0.390.531.32 (0.55--3.16)009:020 (0.0)2 (0.5)010:0122 (26.8)89 (22.6)012:013 (3.7)24 (6.1)0170 (0.0)5 (1.3)018:010 (0.0)1 (0.3)0198 (9.8)22 (5.6)0270 (0.0)24 (6.1)0330 (0.0)1 (0.3)0451 (1.2)15 (3.8)04920 (24.4)17 (4.3)38.166.52 × 10^−10^7.15 (3.55--14.41)

The genotype frequencies of *MICA*\*008(:01 or:04)*/MICA*\*049, *MICA*\*010:01*/MICA*\*049 and *MICA*\*049*/MICA*\*049 were significantly higher in the patients (see Supplementary Table [S1](#MOESM1){ref-type="media"}).

The *MICA* allele phenotype frequencies in BD patients and controls were shown in Table [2](#Tab2){ref-type="table"}. The *MICA*\*049 was significantly increased in BD patients compared to that in controls (41.5% versus 8.1%, OR = 8.01, *P = *1.91 × 10^−8^). The difference of the *MICA*\*009 frequency between patients and controls was not significant (17.1% in BD versus 13.2% in control, OR = 1.35, *P* = 0.51). The allele frequency of the *MICA*\*A6 was significantly higher in BD patients than that in controls (32.9% versus 11.7%, OR = 3.71, *P* = 1.18 × 10^−6^). The result of phenotype frequency was consistent with that of allele frequency (53.7% versus 21.8%, OR = 4.15, *P* = 3.16 × 10^−5^).Table 2Phenotype frequencies of *MICA* alleles in BD patients and controls.*MICA* AllelePatients n = 41 (%)Controls n = 197 (%)χ^2^*P* valueOR (95% CI)002:018 (19.5)60 (30.5)0040 (0.0)3 (1.5)007:010 (0.0)5 (2.5)008(:01or :04)11 (26.8)78 (39.6)008:020 (0.0)4 (2.0)009:017 (17.1)24 (12.2)0.430.511.35 (0.54--3.37)009:020 (0.0)2 (1.0)010:0120 (48.8)79 (40.1)012:013 (7.3)23 (11.7)0170 (0.0)4 (2.0)018:010 (0.0)1 (0.5)0198 (19.5)21 (10.7)0270 (0.0)23 (11.7)0330 (0.0)1 (0.5)0451 (2.4)14 (7.1)04917 (41.5)16 (8.1)31.591.91 × 10^−8^8.01 (3.58--17.91)

The presence of *HLA-B*\*51 in BD patients and controls were 46.3% and 15.7% (OR = 4.62, *P* = 1.21 × 10^−5^), respectively (Table [3](#Tab3){ref-type="table"}).Table 3Association of BD with *HLA-B*\*51.Patients n = 41 (%)Controls n = 197 (%)χ^2^*P* valueOR (95% CI)Presence19 (46.3)31 (15.7)19.161.21 × 10^−5^4.62 (2.24--9.54)Absence22 (53.7)166 (84.3)

To examine whether the observed BD association of *MICA*\*049 and *HLA-B*\*51 are independent from each other, we performed subclonal analysis in *HLA-B*\*51 negative subjects for *MICA*\*049, and in *MICA*\*049 negative subjects for *HLA-B*\*51. As shown in Table [4](#Tab4){ref-type="table"}, the *MICA*\*049 remained significantly associated with BD (OR = 40.61, *P* = 0.02) in *HLA-B*\*51 negative BD patients, but the association of *HLA-B*\*51 with BD appeared lost in *MICA*\*049 negative patients (Table [5](#Tab5){ref-type="table"}).Table 4Association of *MICA*\*049 with BD stratified for the effect of *HLA-B*\*51.*MICA*\*049Absence of *HLA-B*\*51Presence of *HLA-B*\*51PatientsControlsPatientsControlsPresence201516Absence20166415χ^2^15.253.74*P* value0.020.07OR (95% CI)40.61 (1.88--875.58)3.52 (0.95--13.01)Table 5Association of *HLA-B*\*51 with BD stratified for the effect of *MICA*\*049.*HLA-B*\*51Absence of *MICA*\*049Presence of *MICA*\*049PatientsControlsPatientsControlsPresence4151516Absence2016620χ^2^1.772.00*P* value0.250.29OR (95% CI)2.21 (0.67--7.32)0.19 (0.01--4.23)

Discussion {#Sec3}
==========

Previously, *MICA*\*009 and *MICA*\*A6 were suggested as susceptibility alleles for BD. The *MICA*\*A6 is a polymorphism with 6 tendent repeats of GCT in exon 5 of *MICA* gene. This polymorphism is included in the *MICA*\*009, and shared by *MICA*\*049 and a number of other *MICA* alleles. In the previous studies^[@CR5],[@CR8]--[@CR11]^, the *MICA* alleles were identified by PCR-SSP or PCR-SBT based on sequences of exon 2 to exon 5. However, the *MICA*\*00901 and the *MICA*\*049 differ by only one nucleotide at codon 335 of exon 6. Therefore, the ambiguity between these two alleles could not be addressed, and the *MICA*\*009 allele reported in the previous studies may be mixed with *MICA*\*049. According to allelic functional analysis using SIFT program (<http://sift.bii.a-star.edu.sg/>), the change at codon 335 may impact MICA function.

In the present study, we developed a rapid and cost-efficient T-ARMS-PCR to discriminate the *MICA*\*009 from the *MICA*\*049. Comparison analysis between BD patients and controls showed that the *MICA*\*049, not \*009, was strongly associated with BD. As we expected, the *MICA*\*A6 showed a consistent BD association with previous reports as it is within the *MICA*\*049 polymorphism. It is worth noting that the allele frequency of the *MICA*\*009 and \*049 in controls were consistent with the previous report of *MICA* alleles in a Chinese population^[@CR12]^. Considering *MICA* and *HLA-B* genes are located next to each other, and strong linkage disequilibrium (LD) exists between alleles of these two genes, it is necessary to determine whether the observed association is due to LD effect from *HLA-B*\*51. According to the clonal analysis, the *MICA*\*049 was independently associated with BD in the Chinese cohort.

In conclusion, we investigated *MICA* polymorphisms in patients with BD of Chinese Han. It is the first report of *MICA*\*049 in association with BD, and which appeared independent from *HLA-B*\*51. Although the sample size is relatively small in the study, the association achieved significant p value with strong odd ratio. However, it still warrants further validation studies in a larger Chinese cohort and/or other ethnic populations. It may not rule out this observed association is ethnic specific for Chinese Han population.

Methods {#Sec4}
=======

Participants {#Sec5}
------------

A total of 41 Patients (34 male, 7 female) were enrolled between March 2010 and September 2017 from the Eye Hospital of Wenzhou Medical University. The diagnosis of BD was followed the criteria of the International Study Group of BD^[@CR13]^. The mean age of the patients was 37.8 years (range between 27--50 years) and the mean duration of the disease was 6.4 years (range between 1--18 years). A total of 197 unrelated healthy individuals were recruited in the same geography. All of patients and controls were Chinese Han. The study was approved by the Ethics Committee of the Eye Hospital of Wenzhou Medical University and was conducted according to the Declaration of Helsinki Principles. Written inform consent was obtained from all participants.

Genomic DNA extraction {#Sec6}
----------------------

Genomic DNA was extracted from peripheral blood cells of all subjects using Bioteke DNA isolation kit (Beijing, China). After detecting DNA concentration by a Nanodrop 2000 spectrophotometer, a part of DNA of each subject was diluted to 10 ng/μl for genotyping assays.

*HLA-B*\*51 genotyping {#Sec7}
----------------------

For control samples, the *HLA-B*\*51 genotyping was performed with sequence-based typing (SBT) method using secore kits (Life Technologies, USA)^[@CR14]^. For patients, each sample was genotyped for *HLA-B*\*51 positivity by ARMS PCR method^[@CR15]^.

*MICA* genotyping {#Sec8}
-----------------

*MICA* was genotyped by PCR sequencing exon 2--5 regions using bidirectional Sanger sequencing methods^[@CR16]^. For samples in patient group which were discriminated as *MICA*\*009:01/\*049, Sanger sequencing was used to distinguished the two alleles. Two primers (Forward primer: 5′-AGAGAAAGGGCGAATCTGGT-3′, Reverse primer: 5′-AAGAGGGAAA-GTGCTCGTGA-3′) were used to amplify 301 bp PCR products. The PCR was performed in a total volume of 20 μl containing 10 μl of 2 × Taq Master Mix (Jinan, Shanghai, China), 0.4 μM of each primer (Invitrogen, Shanghai, China) and 10 ng of genomic DNA. PCR was carried out on a Veriti Thermal cycler. The PCR thermal cycling condition was an initial denaturation at 94 °C for 3 min, followed by 35 cycles at 94 °C for 20 s, 60 °C for 20 s and 72 °C for 20 s, and a final extension at 72 °C for 5 min. For samples in control group which were detected as *MICA*\*009:01/\*049, T-ARMS-PCR was used to differentiate *MICA*\*009:01 from *MICA*\*049. The sequence of the four primers and concentration of each primer were listed in Table [6](#Tab6){ref-type="table"}. Product sizes were 246 bp for T allele, 182 bp for C allele, and 382 bp for the forward outer primer and reverse outer primer. The PCR was performed in a final volume of 10 μl containing 5 μl of 2 × Hot-start Taq Red Master Mix (PHENIX, CA, USA), 0.4--1.4 μM of each primer (IDT, Skokie, USA) and 10 ng of genomic DNA. The PCR program on the Veriti Thermal cycler was as follow: 95 °C for 10 min; 35 cycles of 20 s at 94 °C, 30 s at 62 °C and 25 s at 72 °C, followed by a final extension of 5 min at 72 °C. The results of T-ARMS-PCR were verified by DNA sequencing. Direct sequencing was done with the two outer primers. The PCR products were purified using DNA clean & concentrator kit (Irvine, CA, USA), then the purified PCR products were sent to company for sequencing (GENEWIZ, NJ, USA). The sequencing data were analyzed using chromas software.Table 6Primers for the T-ARMS-PCR to distinguish *MICA*\*009:01 from *MICA*\*049.PrimerSequence (5′ to 3′)Concentration (μM)FOGATGGGAGGGAACTGGTAGGGGCT0.4FIGGTCCTGGATCAACACCCAGTTGGTAC0.8RIGGCATCCCTGTGGTCACGCA1.4ROAGGCACCAAGAGGGAAAGTGCTCG0.4FO: Forward outer primer, FI: Forward inner primer, RI: Reverse inner primer, RO: Reverse outer primer.

Statistical analysis {#Sec9}
--------------------

*HLA-B*\*51 and *MICA* allelic frequencies were calculated by direct counting. The significance of the distribution of alleles between the patient group and the control group was calculated by Chi-square or Fisher's exact test using SPSS22.0 or Epi info software. If the cell frequency as zero, the odds ratio (OR) was calculated using MedCalc software ([https://www.medcalc.org/calc/odds_ratio.php](https://www.medcalc.org/calc/odds)).
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Table S1 Comparison of MICA alleles in pair between BD patients and controls
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